Department of Natural Products, National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad, S. G. Highway, Thaltej, Ahmedabad, 380054, Gujarat, India.
Sardar Patel University, Vallabh Vidyanagar, 388120, Gujarat, India.
Chem Biol Interact. 2016 Jul 25;254:83-92. doi: 10.1016/j.cbi.2016.05.031. Epub 2016 May 24.
Picroside I and II, iridoid glycosides, are the major active markers of roots and rhizomes of Picrorhiza kurroa (family: Scrophulariaceae). The rhizomes of P. kurroa have been traditionally used to treat worms, constipation, low fever, scorpion sting, asthma and ailments affecting the liver. Various Ayurvedic and herbal preparations are available in the market which contains P. kurroa e.g. Arogyavadhini vati, Tiktadi kwath, Picrolax capsules and suspension. These preparations are used without any significant pharmacokinetics data. Previously, we have reported that oral bioavailability of picroside I and II is low. Most of the iridoid glycosides are primarily metabolized by intestinal microbial flora. So, it is necessary to determine the metabolic profile of picroside I and II and check the correlation with lower bioavailability. Therefore, this study was designed to check metabolic (in vitro and in vivo) profile along with pharmacokinetic profile of picroside I and II. For this, a sensitive and selective LC-ESI-MS method was developed and validated for simultaneous determination of picroside I and II in rat plasma. Chromatographic separations were performed on C18 column. The mobile phase consisted of acetonitrile: 10 mM ammonium acetate buffer [90:10 v/v], pH 3.5. In-vitro Metabolic study was performed on rat liver microsomes and primary hepatocytes. In-vivo pharmacokinetic and metabolic profile of picroside I and II was generated after oral administration of Kutkin (mixture of picroside I and II) to Sprague-Dawley rats. Various pharmacokinetic parameters viz. Cmax, Tmax, AUC(0-t) were determined. In metabolic study, eight metabolites of picroside I and six metabolites of picroside II were identified in vitro, out of which four metabolites for each picroside I and picroside II were identified in vivo.
胡黄连苷 I 和 II 是玄参科胡黄连属植物胡黄连(Picrorhiza kurroa)根及根茎的主要活性成分,具有杀虫、通便、退低热、解蝎毒、平喘、利胆等功效。市场上有多种含有胡黄连的阿育吠陀制剂和草药制剂,例如 Arogyavadhini vati、Tiktadi kwath、Picrolax 胶囊和混悬剂。这些制剂在没有任何显著药代动力学数据的情况下使用。先前,我们已经报道胡黄连苷 I 和 II 的口服生物利用度较低。大多数裂环烯醚萜类糖苷主要由肠道微生物菌群代谢。因此,有必要确定胡黄连苷 I 和 II 的代谢谱,并检查其与较低生物利用度的相关性。因此,本研究旨在检查胡黄连苷 I 和 II 的代谢(体外和体内)谱以及药代动力学谱。为此,开发并验证了一种灵敏、选择性的 LC-ESI-MS 方法,用于同时测定大鼠血浆中的胡黄连苷 I 和 II。色谱分离在 C18 柱上进行。流动相由乙腈:10 mM 乙酸铵缓冲液[90:10 v/v],pH 3.5 组成。在大鼠肝微粒体和原代肝细胞中进行体外代谢研究。在 Sprague-Dawley 大鼠口服 Kutkin(胡黄连苷 I 和 II 的混合物)后,生成胡黄连苷 I 和 II 的体内药代动力学和代谢谱。确定了各种药代动力学参数,如 Cmax、Tmax、AUC(0-t)。在代谢研究中,在体外鉴定了胡黄连苷 I 的 8 种代谢物和胡黄连苷 II 的 6 种代谢物,其中胡黄连苷 I 和 II 各有 4 种代谢物在体内鉴定。